Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or with meropenem

Journal of Infection and Public Health

Volumn 10, Issue 6, 2017, Pages 770-773

  Al Yami, Majed S ^a,b  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute kidney injury; Meropenem; Nephrotoxicity; Piperacillin tazobactam; Vancomycin

Indexed keywords

CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; THIENAMYCINS; VANCOMYCIN; YOUNG ADULT;

EID: 85012031651     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2016.11.007     Document Type: Article

References (18)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2:Suppl (2012), 1–138.
2. Elyasi, S., Khalili, H., Dashti-Khavidaki, S., Mohammadpour, A., Vancomycin induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68 (2012), 1243–1255.
3. Van Hal, S.J., Paterson, D.L., Lodise, T.P., Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter antimicrob. Agents Chemother, 57(2), 2013, 734.
4. Carreno, J., Kenney, R., Lomaestro, B., Vancomycin-associated renal dysfunction: where are we now?. Pharmacotherapy 34:12 (2014), 1259–1268.
5. Pfizer, Zosyn (piperacillin-tazobactam) package insert. 2012, Pfizer, Philadelphia, PA.
6. Moenster, R.P., Linneman, T.W., Finnegan, P.M., Hand, S., Thomas, Z., McDonald, J.R., Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin/tazobactam compared to cefepime. Clin Microbiol Infect 20:6 (2014), O384–O389.
7. Gomes, D.M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B.J., Kraemer, D.F., et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or cefepime. Pharmacotherapy 34 (2014), 662–669.
8. Burgess, L.D., Drew, R.H., Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin–tazobactam. Pharmacotherapy 34 (2014), 670–676.
9. Min, E., Box, K., Lane, J., Sanchez, J., Coimbra, R., Doucet, J., et al. Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. Crit Care Med, 39, 2011, 200 [abstract 714].
10. Meaney, C.J., Hynicka, L.M., Tsoukleris, M.G., Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34 (2014), 653–661.
11. AstraZeneca, Merrem (meropenem) package insert. 2014, AstraZeneca, Wilmington, DE Revised 2015 April.
12. Hammond, D.A., Smith, M.N., Painter, J.T., Meena, N.K., Lusardi, K., Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy 36 (2016), 463–471.
13. Vincent, P., Samantha, S., Henry, C., Prospective comparison of acute kidney injury during treatment with the combination of piperacillin–tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. Journal of Pharmacy Practice, 2016, 10.1177/0897190016628960 first published on February 23.
14. Gupta, A., Biyani, M., Khaira, A., Vancomycin nephrotoxicity: myths and facts. Neth J Med 69 (2011), 379–383.
15. Rybak, M., Lomaestro, B., Rotschafer, J., Moellering, R., Craig, W., Billeter, M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:1 (2009), 82–98.
16. Jensen, J., Hein, L., Lundgren, B., Bestle, M.H., Mohr, T., Andersen, M.H., et al. Kidney failure related to broad-spectrum antibiotics in critically-ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open, 2(2), 2012, e000635.
17. Liu, T., Lam, J., Piperacillin–tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis. Am J Health Syst Pharm, 69(13), 2012, 1109.
18. Pratt, J., Stricherz, M., Verghese, P., Burke, M.J., Suspected piperacillin tazobactam induced nephrotoxicity in the pediatric oncology population. Pediatr Blood Cancer 61:12 (2014), 366–368.